#30: TheMachine: Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
Final Unblinded Results Are Expected to Confirm Efficacy Of BiovaxID... |
June 12, 2008
07:45:08 AM |
#29: NewsBot: Accentia Biopharmaceuticals Reports Fiscal First Quarter 2008 Financial Results
Company Affirms Plans to Unblind and Report Fast Track Pivotal
Phase 3... |
February 20, 2008
06:18:10 PM |
#28: NewsBot: End of Year Reported at Accentia Biopharmaceuticals
Accentia Biopharmaceuticals Reports Fiscal
2007 Year-End Results; Pivotal Phase... |
December 29, 2007
08:11:44 AM |
#27: Jason: Biovest International to Present at Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
Biovest International, Inc. (OTCBB:BVTI), a majority owned subsidiary of
... |
November 21, 2007
10:36:29 AM |
#26: NewsBot: ABPI News Accentia Biopharmaceuticals Continues Nationwide Education Initiative to Promote Better Understanding of Chronic Sinusitis
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals (NASDAQ:ABPI) --... |
March 8, 2007
05:15:00 AM |
#25: NewsBot: ABPI News Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI),... |
March 7, 2007
05:00:00 AM |
#24: NewsBot: ABPI News Accentia Biopharmaceuticals Acquires Worldwide Exclusive License to Revimmune for All Autoimmune Diseases
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) has... |
February 28, 2007
06:04:00 AM |
#23: NewsBot: ABPI News Accentia Biopharmaceuticals, Inc. Enters Into a Definitive Agreement for a $20 Million Convertible Debenture Financing
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)... |
February 28, 2007
06:03:00 AM |
#22: NewsBot: ABPI News Accentia Biopharmaceuticals Fiscal 2006 Audit
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)... |
January 9, 2007
01:43:00 PM |
#21: NewsBot: ABPI News Accentia Biopharmaceuticals Reports Fiscal 2006 Year-End Results
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI;... |
January 1, 2007
06:00:00 AM |
#20: NewsBot: ABPI News Accentia Biopharmaceuticals in Discussions with Pharmaceutical Companies on SinuNase Partnership
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals (NASDAQ: ABPI) ... |
December 21, 2006
08:15:00 AM |
#19: NewsBot: ABPI News Surveys Confirm Clinical Acceptance of Fungal Etiology in Chronic Sinusitis
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI),... |
November 28, 2006
05:00:00 AM |
#18: NewsBot: ABPI News Report Shows Use of a SinuNase Formulation is Associated With a Significant, 74% Reduction in Reoperations for Chronic Sinusitis Patients Who Are Refractory to Sinus Surgery
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals (NASDAQ: ABPI) ... |
November 9, 2006
05:00:00 AM |
#17: NewsBot: ABPI News Accentia Biopharmaceuticals Commences Fast-Tracked Phase 3 Clinical Trial of SinuNase for the Treatment of Chronic Sinusitis
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals (NASDAQ: ABPI) ... |
November 6, 2006
05:05:00 AM |
#16: NewsBot: ABPI News Accentia Biopharmaceuticals Majority-Owned Subsidiary Commercially Launches AutovaxID(TM)
TAMPA, Fla.--(BUSINESS WIRE)--A majority-owned subsidiary of Accentia... |
November 1, 2006
11:53:00 AM |
| 
| 
| 
| 
| 
| 
